Panhypopituitarism

What is Panhypopituitarism?
Panhypopituitarism is a condition of inadequate or absent production of the anterior pituitary hormones. It is frequently the result of other problems that affect the pituitary gland and either reduce or destroy its function or interfere with hypothalamic secretion of the varying pituitary-releasing hormones. More information about Panhypopituitarism may be found on the NIH’s website: https://www.ncbi.nlm.nih.gov/books/NBK470414/ 

What is the prevalence of Panhypopituitarism?
Internationally, hypopituitarism has an estimated incidence of 4.2 cases per 100,000 per year and an estimated prevalence of 45.5 cases per 100,000 without gender difference. 

How is Panhypopituitarism diagnosed?
The diagnosis of hypopituitarism is made by measuring basal hormone levels in the morning fasting status or performing stimulation tests if necessary. Six anterior pituitary hormones (GH, prolactin, LH, FSH, TSH, and ACTH) as well as target hormones can be measured via sensitive and reliable immunoassay techniques.

Is there any specific gene/pathway in Panhypopituitarism that has been identified?
Mutations in any of the genes involved in pituitary development may result in congenital hypopituitarism leading to deficiency in one or more pituitary hormones. There are five specific genes commonly associated with a diagnosis: POU1F1, PROP1, LHX3, LHX4, and HESX1.

How is Panhypopituitarism treated?
Most symptoms of Panhypopituitarism are irreversible. Accordingly, the primary goals of treatment should be centered around the recuperation of the physiological health of the patient in terms of growth, reproduction, metabolism, and body composition. This may be achieved through, among other treatments, hormone replacement therapy.

Are there any clinical trials underway for Panhypopituitarism?
The National Institutes of Health (NIH) has completed 2 clinical trials for Panhypopituitarism. Currently, there are 4 clinical trials underway for the condition. More information on future studies and patient recruitment can be found here: https://clinicaltrials.gov

How can RareShare be helpful to Panhypopituitarism patients and families?
The PanhypopituitarismRareshare community has 40 members. There are currently 15 active discussions underway. New discussions can help to connect patients, health workers, caregivers and families interested in Panhypopituitarismand provide them continual access to community resources.